$1.7B Humira IP Verdict Won't Get Supreme Court Review

Law360, New York (February 21, 2012, 7:30 PM EST) -- The U.S. Supreme Court on Tuesday declined to review a Federal Circuit ruling that negated a $1.67 billion patent verdict against Abbott Laboratories, refusing to consider a Johnson & Johnson unit's argument that the written description requirement used by the appeals court is too unpredictable.

A Texas jury found in 2009 that Abbott's arthritis drug Humira infringed a patent held by J&J unit Janssen Biotech Inc. and issued the largest patent verdict in U.S. history. However, the Federal Circuit ruled in February 2011 that Janssen's patent...
To view the full article, register now.